HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZESTRIL safely and effectively. See full prescribing information for ZESTRIL ZESTRIL[®] (lisinopril) tablets, for oral use Initial U.S. Approval: 1988

WARNING: FETAL TOXICITY

See full prescribing information for complete boxed warning.

• When pregnancy is detected, discontinue Zestril as soon as possible. (5.1)

 Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)

..... INDICATIONS AND USAGE

Zestril is an angiotensin converting enzyme (ACE) inhibitor indicated for:

- Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1)
- Adjunct therapy for heart failure (1.2)
- Treatment of Acute Myocardial Infarction (1.3)
- ----- DOSAGE AND ADMINISTRATION
- Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily (2.1)
- Pediatric patients with glomerular filtration rate $> 30 \text{ mL/min/}1.73\text{m}^2$: Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily (2.1)
- Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily (2.2)
- Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily (2.3)
- Renal Impairment: For patients with creatining clearance ≥ 10 mL/min and ≤ 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the recommended initial dose is 2.5 mg (2.4)

------ DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg (3) ------ CONTRAINDICATIONS ------

- Angioedema or a history of hereditary or idiopathic angioedema (4)
- Hypersensitivity (4)
- Co-administration of aliskiren with Zestril in patients with diabetes (4, 7.4)

------ WARNINGS AND PRECAUTIONS ------

- Angioedema: Discontinue Zestril, provide appropriate therapy and monitor until resolved (5.2)
- Renal impairment: Monitor renal function periodically (5.3)
- Hypotension: Patients with other heart or renal diseases have increased risk, monitor blood pressure after initiation (5.4)
- Hyperkalemia: Monitor serum potassium periodically (5.5)
- Cholestatic jaundice and hepatic failure: Monitor for jaundice or signs of liver failure (5.6)

ADVERSE REACTIONS	
Common adverse reactions (events 2% greater than placebo) by use:	

• Hypertension: headache, dizziness and cough (6.1)

- Heart Failure: hypotension and chest pain (6.1)
- Acute Myocardial Infarction: hypotension (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact TWi Pharmaceuticals, Inc. at 1-844-518-2989 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Diuretics: Excessive drop in blood pressure (7.1)
- NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy (7.3)
- Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia (7.4)
- Lithium: Symptoms of lithium toxicity (7.5)
- Gold: Nitritoid reactions have been reported (7.6)
- Concomitant mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7, 7.8)
- Lactation: Advise not to breastfeed. (8.2)
- Race: Less antihypertensive effect in blacks than non blacks (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 1/2024

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: FETAL TOXICITY

- **1 INDICATIONS AND USAGE**
 - 1.1 Hypertension
 - **1.2 Heart Failure**
 - **1.3 Reduction of Mortality in Acute Myocardial Infarction**
- **2 DOSAGE AND ADMINISTRATION**
 - 2.1 Hypertension
 - 2.2 Heart Failure
 - 2.3 Reduction of Mortality in Acute Myocardial Infarction
 - 2.4 Dose in Patients with Renal Impairment
- **3 DOSAGE FORMS AND STRENGTHS**
- **4 CONTRAINDICATIONS**
- **5 WARNINGS AND PRECAUTIONS**
 - 5.1 Fetal Toxicity
 - 5.2 Angioedema and Anaphylactoid Reactions
 - 5.3 Impaired Renal Function
 - 5.4 Hypotension
 - 5.5 Hyperkalemia
 - 5.6 Hepatic Failure
- **6 ADVERSE REACTIONS**
 - 6.1 Clinical Trials Experience
 - 6.2 Post-marketing Experience
- 7 DRUG INTERACTIONS
 - 7.1 Diuretics
 - 7.2 Antidiabetics
 - 7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
 - 7.4 Dual Blockade of the Renin-Angiotensin System (RAS)
 - 7.5 Lithium
 - 7.6 Gold
 - 7.7 mTOR Inhibitors
 - 7.8 Neprilysin Inhibitor

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Race
- 8.7 Renal Impairment
- **10 OVERDOSAGE**

11 DESCRIPTION

- **12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
 - **12.2 Pharmacodynamics**
 - **12.3 Pharmacokinetics**

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- **14 CLINICAL STUDIES**
 - 14.1 Hypertension
 - 14.2 Heart Failure
 - **14.3 Acute Myocardial Infarction**

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: FETAL TOXICITY

- When pregnancy is detected, discontinue ZESTRIL as soon as possible [see Warnings and Precautions (5.1)].
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

1.1 Hypertension

Zestril is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Zestril may be administered alone or with other antihypertensive agents [see Clinical Studies (14.1)].

1.2 Heart Failure

Zestril is indicated to reduce signs and symptoms of systolic heart failure [see Clinical Studies (14.2)].

1.3 Reduction of Mortality in Acute Myocardial Infarction

Zestril is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers [see Clinical Studies (14.3)].

2 DOSAGE AND ADMINISTRATION

2.1 Hypertension

Initial Therapy in adults: The recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20 mg to 40 mg per day administered in a single daily dose. Doses up to 80 mg have been used but do not appear to give greater effect.

Use with diuretics in adults

If blood pressure is not controlled with Zestril alone, a low dose of a diuretic may be added (e.g., hydrochlorothiazide, 12.5 mg). After the addition of a diuretic, it may be possible to reduce the dose of Zestril.

The recommended starting dose in adult patients with hypertension taking diuretics is 5 mg once per day.

Pediatric Patients 6 years of age and older with hypertension

For pediatric patients with glomerular filtration rate > 30 mL/min/1.73m², the recommended starting dose is 0.07 mg per kg once daily (up to 5 mg total). Dosage should be adjusted according to blood pressure response up to a maximum of 0.61 mg per kg (up to 40 mg) once daily. Doses above 0.61 mg per kg (or in excess of 40 mg) have not been studied in pediatric patients [see Clinical Pharmacology (12.3)].

Zestril is not recommended in pediatric patients < 6 years or in pediatric patients with glomerular filtration rate < 30 mL/min/ $1.73m^2$ [see Use in Specific Populations (8.4) and Clinical Studies (14.1)].

2.2 Heart Failure

The recommended starting dose for Zestril, when used with diuretics and (usually) digitalis as adjunctive therapy for systolic heart failure, is 5 mg once daily. The recommended starting dose in these patients with hyponatremia (serum sodium < 130 mEq/L) is 2.5 mg once daily. Increase as tolerated to a maximum of 40 mg once daily.

Diuretic dose may need to be adjusted to help minimize hypovolemia, which may contribute to hypotension [see Warnings and Precautions (5.4), and Drug Interactions (7.1)]. The appearance of hypotension after the initial dose of Zestril does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension.

2.3 Reduction of Mortality in Acute Myocardial Infarction

In hemodynamically stable patients within 24 hours of the onset of symptoms of acute myocardial infarction, give Zestril 5 mg orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Dosing should continue for at least six weeks.

Initiate therapy with 2.5 mg in patients with a low systolic blood pressure (\leq 120 mmHg and > 100 mmHg) during the first 3 days after the infarct [see Warnings and *Precautions (5.4)*]. If hypotension occurs (systolic blood pressure \leq 100 mmHg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure < 90 mmHg for more than 1 hour) Zestril should be withdrawn.

2.4 Dose in Patients with Renal Impairment

No dose adjustment of Zestril is required in patients with creatinine clearance > 30 mL/min. In patients with creatinine clearance ≥ 10 mL/min and ≤ 30 mL/min, reduce the initial dose of Zestril to half of the usual recommended dose i.e., hypertension, 5 mg; systolic heart failure, 2.5 mg and acute MI, 2.5 mg. Up titrate as tolerated to a maximum of 40 mg daily. For patients on hemodialysis or creatinine clearance < 10 mL/min, the recommended initial dose is 2.5 mg once daily [see Use in Specific Populations (8.7) and

3 DOSAGE FORMS AND STRENGTHS

2.5 mg are white, round, biconvex, uncoated tablets identified as "ZESTRIL 2 1/2" on one side and "135" on the other side.

5 mg are pink, capsule-shaped, biconvex, bisected, uncoated tablets identified as "ZESTRIL" on one side and "130" on the other side.

10 mg are pink, round, biconvex, uncoated tablets identified as "ZESTRIL 10" on one side and "131" on the other side.

20 mg are pale brownish red, round, biconvex, uncoated tablets identified as "ZESTRIL 20" on one side and "132" on the other side.

30 mg are pale brownish red, round, biconvex, uncoated tablets identified as "ZESTRIL 30" on one side and "133" on the other side.

40 mg are yellow, round, biconvex, uncoated tablets identified as "ZESTRIL 40" on one side and "134" on the other side.

4 CONTRAINDICATIONS

Zestril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2)].

Zestril is contraindicated in patients with:

- a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor
- hereditary or idiopathic angioedema

Do not co-administer aliskiren with ZESTRIL in patients with diabetes [see Drug Interactions (7.4)].

5 WARNINGS AND PRECAUTIONS

5.1 Fetal Toxicity

Zestril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Zestril as soon as possible [see Use in specific Populations (8.1)].

5.2 Angioedema and Anaphylactoid Reactions

Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema. *[see Drug Interactions (7.7, 7.8)]*.

Angioedema

Head and Neck Angioedema

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx, including some fatal reactions, have occurred in patients treated with angiotensin converting enzyme inhibitors, including Zestril, at any time during treatment. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Zestril should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms of angioedema has occurred.

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [see Contraindications (4)]. ACE inhibitors have been associated with a higher rate of angioedema in black than in non-black patients.

Intestinal Angioedema

Intestinal angioedema has occurred in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. In some cases, the angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor.

Anaphylactoid Reactions

Anaphylactoid Reactions During Desensitization

Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life- threatening anaphylactoid reactions.

Anaphylactoid Reactions During Dialysis

Sudden and potentially life threatening anaphylactoid reactions have occurred in some patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for anaphylactoid reactions must be initiated. Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing lowdensity lipoprotein apheresis with dextran sulfate absorption.

5.3 Impaired Renal Function

Monitor renal function periodically in patients treated with Zestril. Changes in renal function including acute renal failure can be caused by drugs that inhibit the reninangiotensin system. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, post-myocardial infarction or volume depletion) may be at particular risk of developing acute renal failure on Zestril. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on Zestril [see Adverse Reactions (6.1), Drug Interactions (7.4)].

5.4 Hypotension

Zestril can cause symptomatic hypotension, sometimes complicated by oliguria, progressive azotemia, acute renal failure or death. Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology.

In these patients, Zestril should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of Zestril and/or diuretic is increased. Avoid use of Zestril in patients who are hemodynamically unstable after acute MI.

Symptomatic hypotension is also possible in patients with severe aortic stenosis or hypertrophic cardiomyopathy.

Surgery/Anesthesia

In patients undergoing major surgery or during anesthesia with agents that produce hypotension, Zestril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

5.5 Hyperkalemia

Serum potassium should be monitored periodically in patients receiving Zestril. Drugs that inhibit the renin angiotensin system can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1)].

5.6 Hepatic Failure

ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and sometimes death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical treatment.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Hypertension

In clinical trials in patients with hypertension treated with Zestril, 5.7% of patients on Zestril discontinued with adverse reactions.

The following adverse reactions (events 2% greater on Zestril than on placebo) were observed with Zestril alone: headache (by 3.8%), dizziness (by 3.5%), cough (by 2.5%).

<u>Heart Failure</u>

In patients with systolic heart failure treated with Zestril for up to four years, 11% discontinued therapy with adverse reactions. In controlled studies in patients with heart failure, therapy was discontinued in 8.1% of patients treated with Zestril for 12 weeks, compared to 7.7% of patients treated with placebo for 12 weeks.

The following adverse reactions (events 2% greater on Zestril than on placebo) were observed with Zestril: hypotension (by 3.8%), chest pain (by 2.1%).

In the two-dose ATLAS trial [see Clinical Studies (14.2)] in heart failure patients, withdrawals due to adverse reactions were not different between the low and high groups, either in total number of discontinuation (17% to 18%) or in rare specific reactions (< 1%). The following adverse reactions, mostly related to ACE inhibition, were reported more commonly in the high dose group:

	High Dose (n=1568)	Low Dose (n=1596)
Dizziness	19%	12%
Hypotension	11%	7%
Creatinine increased	10%	7%
Hyperkalemia	6%	4%
Syncope	7%	5%

Table 1 Dose-related Adverse Drug Reactions: ATLAS trial

Acute Myocardial Infarction

Patients treated with Zestril had a higher incidence of hypotension (by 5.3%) and renal dysfunction (by 1.3%) compared with patients not taking Zestril.

Other clinical adverse reactions occurring in 1% or higher of patients with hypertension or heart failure treated with Zestril in controlled clinical trials and do not appear in other sections of labeling are listed below:

Body as a whole: Fatigue, asthenia, orthostatic effects.

Digestive: Pancreatitis, constipation, flatulence, dry mouth, diarrhea.

<u>Hematologic</u>: Rare cases of bone marrow depression, hemolytic anemia, leukopenia/neutropenia and thrombocytopenia.

Endocrine: Diabetes mellitus, inappropriate antidiuretic hormone secretion.

<u>Metabolic</u>: Gout.

<u>Skin</u>: Urticaria, alopecia, photosensitivity, erythema, flushing, diaphoresis, cutaneous pseudolymphoma, toxic epidermal necrolysis, Stevens - Johnson syndrome, and

pruritus.

<u>Special Senses</u>: Visual loss, diplopia, blurred vision, tinnitus, photophobia, taste disturbances, olfactory disturbance.

Urogenital: Impotence.

<u>Miscellaneous</u>: A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia, leukocytosis, paresthesia and vertigo. Rash, photosensitivity or other dermatological manifestations may occur alone or in combination with these symptoms.

Clinical Laboratory Test Findings

<u>Serum Potassium</u>: In clinical trials hyperkalemia (serum potassium greater than 5.7 mEq/L) occurred in 2.2% and 4.8% of Zestril-treated patients with hypertension and heart failure, respectively [see Warnings and Precautions (5.5)].

Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 2% of patients with hypertension treated with Zestril alone. Increases were more common in patients receiving concomitant diuretics and in patients with renal artery stenosis [see Warnings and Precautions (5.4)]. Reversible minor increases in blood urea nitrogen and serum creatinine were observed in 11.6% of patients with heart failure on concomitant diuretic therapy. Frequently, these abnormalities resolved when the dosage of the diuretic was decreased.

Patients with acute myocardial infarction in the GISSI-3 trial treated with Zestril had a higher (2.4% versus 1.1% in placebo) incidence of renal dysfunction in-hospital and at six weeks (increasing creatinine concentration to over 3 mg/dL or a doubling or more of the baseline serum creatinine concentration).

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.4 g% and 1.3 vol%, respectively) occurred frequently in patients treated with Zestril but were rarely of clinical importance in patients without some other cause of anemia. In clinical trials, less than 0.1% of patients discontinued therapy due to anemia.

6.2 Post-marketing Experience

The following adverse reactions have been identified during post-approval use of Zestril that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Other reactions include:

Metabolism and nutrition disorders

Hyponatremia [see Warnings and Precautions (5.4)], cases of hypoglycemia in diabetic patients on oral antidiabetic agents or insulin [see Drug Interactions (7.2)].

Nervous system and psychiatric disorders

Mood alterations (including depressive symptoms), mental confusion, hallucinations

Psoriasis

7 DRUG INTERACTIONS

7.1 Diuretics

Initiation of Zestril in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with Zestril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Zestril. If this is not possible, reduce the starting dose of Zestril [see Dosage and Administration (2.2) and Warnings and Precautions (5.4)].

Zestril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.

7.2 Antidiabetics

Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia.

7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.

The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs.

7.4 Dual Blockade of the Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

The VA NEPHRON trial enrolled 1,448 patients with type 2 diabetes, elevated urinaryalbumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 mL/min to 89.9 mL/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal

function and electrolytes in patients on Zestril and other agents that affect the RAS.

Do not co-administer aliskiren with Zestril in patients with diabetes. Avoid use of aliskiren with Zestril in patients with renal impairment (GFR <60 mL/min).

7.5 Lithium

Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs, which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. Monitor serum lithium levels during concurrent use.

7.6 Gold

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including Zestril.

7.7 mTOR Inhibitors

Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema. *[see Warnings and Precautions (5.2)]*

7.8 Neprilysin Inhibitor

Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. [see Warnings and Precautions (5.2)]

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Zestril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue Zestril as soon as possible.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for

intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly.

Fetal/Neonatal Adverse Reactions

Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia and skeletal deformations, including skull hypoplasia, hypotension, and death. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the reninangiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.

Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of *in utero* exposure to Zestril for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occur in neonates with a history of *in utero* exposure to Zestril, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function.

8.2 Lactation

Risk Summary

No data are available regarding the presence of lisinopril in human milk or the effects of lisinopril on the breastfed infant or on milk production. Lisinopril is present in rat milk. Because of the potential for severe adverse reactions in the breastfed infant, advise women not to breastfeed during treatment with Zestril.

8.4 Pediatric Use

Antihypertensive effects and safety of Zestril have been established in pediatric patients aged 6 to 16 years [see Dosage and Administration (2.1) and Clinical Studies (14.1)]. No relevant differences between the adverse reaction profile for pediatric patients and adult patients were identified.

Safety and effectiveness of Zestril have not been established in pediatric patients under the age 6 or in pediatric patients with glomerular filtration rate < 30 mL/min/1.73 m²[see Dosage and Administration (2.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)].

Neonates with a history of in utero exposure to Zestril

If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.

8.5 Geriatric Use

No dosage adjustment with Zestril is necessary in elderly patients. In a clinical study of Zestril in patients with myocardial infarctions (GISSI-3 Trial) 4,413 (47%) were 65 and over, while 1,656 (18%) were 75 and over. In this study, 4.8 % of patients aged 75 years and older discontinued Zestril treatment because of renal dysfunction vs. 1.3% of

patients younger than 75 years. No other differences in safety or effectiveness were observed between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

8.6 Race

ACE inhibitors, including Zestril, have an effect on blood pressure that is less in black patients than in non blacks.

8.7 Renal Impairment

Dose adjustment of Zestril is required in patients undergoing hemodialysis or whose creatinine clearance is \leq 30 mL/min. No dose adjustment of Zestril is required in patients with creatinine clearance > 30 mL/min [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].


10 OVERDOSAGE

Following a single oral dose of 20 g/kg no lethality occurred in rats, and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Lisinopril can be removed by hemodialysis [see Clinical Pharmacology (12.3)].

11 DESCRIPTION

Lisinopril is an oral long-acting angiotensin converting enzyme (ACE) inhibitor. Lisinopril, a synthetic peptide derivative, is chemically described as (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate. Its empirical formula is $C_{21}H_{31}N_3O_52H_2O$ and its structural formula is:



Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.53. It is soluble in water and sparingly soluble in methanol and practically insoluble in ethanol.

Zestril is supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets for oral administration.

Inactive Ingredients:

2.5 mg tablets - calcium phosphate, magnesium stearate, mannitol, starch.

5 mg, 10 mg, 20 mg and 30 mg tablets - calcium phosphate, magnesium stearate, mannitol, red ferric oxide, starch.

40 mg tablets - calcium phosphate, magnesium stearate, mannitol, starch, yellow ferric oxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensinaldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with Zestril alone for up to 24 weeks, the mean increase in serum potassium was approximately 0.1 mEg/L; however, approximately 15% of patients had increases greater than 0.5 mEg/L and approximately 6% had a decrease greater than 0.5 mEg/L. In the same study, patients treated with Zestril and hydrochlorothiazide for up to 24 weeks had a mean decrease in serum potassium of 0.1 mEg/L; approximately 4% of patients had increases greater than 0.5 mEg/L and approximately 12% had a decrease greater than 0.5 mEg/L [see Clinical Studies (14.1)]. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Zestril remains to be elucidated.

While the mechanism through which Zestril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, Zestril is antihypertensive even in patients with low-renin hypertension. Although Zestril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to monotherapy than non Black patients.

Concomitant administration of Zestril and hydrochlorothiazide further reduced blood pressure in Black and non-Black patients and any racial differences in blood pressure response were no longer evident.

12.2 Pharmacodynamics

Hypertension

Adult Patients: Administration of Zestril to patients with hypertension results in a reduction of both supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients *[see Warnings and Precautions (5.4)]*. When given together with thiazide-type diuretics, the blood pressure lowering effects of the two drugs are approximately additive.

In most patients studied, onset of antihypertensive activity was seen at one hour after

oral administration of an individual dose of Zestril, with peak reduction of blood pressure achieved by 6 hours. Although an antihypertensive effect was observed 24 hours after dosing with recommended single daily doses, the effect was more consistent and the mean effect was considerably larger in some studies with doses of 20 mg or more than with lower doses; however, at all doses studied, the mean antihypertensive effect was substantially smaller 24 hours after dosing than it was 6 hours after dosing.

The antihypertensive effects of Zestril are maintained during long-term therapy. Abrupt withdrawal of Zestril has not been associated with a rapid increase in blood pressure, or a significant increase in blood pressure compared to pretreatment levels.

Non-Steroidal Anti-Inflammatory Agents

In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of Zestril alone were compared to Zestril given concomitantly with indomethacin, the use of indomethacin was associated with a reduced effect, although the difference between the two regimens was not significant.

12.3 Pharmacokinetics

Adult Patients: Following oral administration of Zestril, peak serum concentrations of lisinopril occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Food does not alter the bioavailability of Zestril. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.

Lisinopril does not appear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25%, with large intersubject variability (6% to 60%) at all doses tested (5mg to 80 mg). The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects. The oral bioavailability of lisinopril in patients with acute myocardial infarction is similar to that in healthy volunteers.

Impaired renal function decreases elimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 mL/min. Above this glomerular filtration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to attain steady state is prolonged [see Dosage and Administration (2.4)]. Lisinopril can be removed by hemodialysis.

Pediatric Patients: The pharmacokinetics of lisinopril were studied in 29 pediatric hypertensive patients between 6 years and 16 years with glomerular filtration rate > 30 mL/min/1.73 m². After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults. The typical value of lisinopril oral clearance (systemic clearance/absolute bioavailability) in a child weighing 30 kg is 10 L/h, which increases in proportion to renal function. In a multicenter, open-label pharmacokinetic study of daily

oral lisinopril in 22 pediatric hypertensive patients with stable kidney transplant (ages 7 to 17 years; estimated glomerular filtration rate > 30 mL/min/1.73 m²), dose normalized exposures were in the range reported previously in children without a kidney transplant.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of a tumorigenic effect when lisinopril was administered for 105 weeks to male and female rats at doses up to 90 mg per kg per day (about 56 or 9 times¹ the maximum recommended daily human dose, based on body weight and body surface area, respectively). There was no evidence of carcinogenicity when lisinopril was administered for 92 weeks to (male and female) mice at doses up to 135 mg per kg per day (about 84 times¹ the maximum recommended daily human dose). This dose was 6.8 times the maximum human dose based on body surface area in mice.

Lisinopril was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. It was also negative in a forward mutation assay using Chinese hamster lung cells. Lisinopril did not produce single strand DNA breaks in an *in vitro* alkaline elution rat hepatocyte assay. In addition, lisinopril did not produce increases in chromosomal aberrations in an *in vitro* test in Chinese hamster ovary cells or in an *in vivo* study in mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with up to 300 mg per kg per day of lisinopril. This dose is 188 times and 30 times the maximum human dose when based on mg/kg and mg/m², respectively.

Studies in rats indicate that lisinopril crosses the blood brain barrier poorly. Multiple doses of lisinopril in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of ¹⁴C lisinopril. By whole body autoradiography, radioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses.

1 Calculations assume a human weight of 50 kg and human body surface area of $1.62m^2$

14 CLINICAL STUDIES

14.1 Hypertension

Two dose-response studies utilizing a once-daily regimen were conducted in 438 mild to moderate hypertensive patients not on a diuretic. Blood pressure was measured 24 hours after dosing. An antihypertensive effect of Zestril was seen with 5 mg of Zestril in some patients. However, in both studies blood pressure reduction occurred sooner and was greater in patients treated with 10 mg, 20 mg or 80 mg of Zestril than patients treated with 5 mg of Zestril.

In controlled clinical studies of patients with mild to moderate hypertension, patients were treated with Zestril 20 mg to 80 mg daily, hydrochlorothiazide 12.5 mg to 50 mg daily or atenolol 50 mg to 200 mg daily; and in other studies of patients with moderate to severe hypertension, patients were treated with Zestril 20 mg to 80 mg daily or metoprolol 100 mg to 200 mg daily. Zestril demonstrated superior reductions of

systolic and diastolic compared to hydrochlorothiazide in a population that was 75% Caucasian. Zestril was approximately equivalent to atenolol and metoprolol in reducing diastolic blood pressure, and had somewhat greater effects on systolic blood pressure.

Zestril had similar blood pressure reductions and adverse effects in younger and older (> 65 years) patients. It was less effective in reducing blood pressure in Blacks than in Caucasians.

In hemodynamic studies of Zestril in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive patients, following administration of Zestril, there was an increase in mean renal blood flow that was not significant. Data from several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not large.

In patients with renovascular hypertension Zestril has been shown to be well tolerated and effective in reducing blood pressure [see Warnings and Precautions (5.3)].

Pediatric Patients: In a clinical study involving 115 hypertensive pediatric patients 6 to 16 years of age, patients who weighed < 50 kg received either 0.625 mg, 2.5 mg or 20 mg of Zestril once daily and patients who weighed ≥ 50 kg received either 1.25 mg, 5 mg, or 40 mg of Zestril once daily. At the end of 2 weeks, Zestril lowered trough blood pressure in a dose-dependent manner with antihypertensive efficacy demonstrated at doses > 1.25 mg (0.02 mg per kg). This effect was confirmed in a randomized withdrawal phase, where the diastolic pressure rose by about 9 mmHg more in patients randomized to placebo than compared to patients who remained on the middle and high doses of lisinopril. The dose-dependent antihypertensive effect of Zestril was consistent across several demographic subgroups: age, Tanner stage, gender, and race. In this study, lisinopril was generally well-tolerated.

In the above pediatric studies, Zestril was given either as tablets or in a suspension for those children and infants who were unable to swallow tablets or who required a lower dose than is available in tablet form [see Dosage and Administration (2.1)].

14.2 Heart Failure

In two placebo controlled, 12-week clinical studies compared the addition of Zestril up to 20 mg daily to digitalis and diuretics alone. The combination of Zestril, digitalis and diuretics reduced the following signs and symptoms of heart failure: edema, rales, paroxysmal nocturnal dyspnea and jugular venous distention. In one of the studies, the combination of Zestril, digitalis and diuretics reduced orthopnea, presence of third heart sound and the number of patients classified as NYHA Class III and IV; and improved exercise tolerance. A large (over 3,000 patients) survival study, the ATLAS Trial, comparing 2.5 mg and 35 mg of lisinopril in patients with systolic heart failure, showed that the higher dose of lisinopril had outcomes at least as favorable as the lower dose.

During baseline-controlled clinical trials, in patients with systolic heart failure receiving digitalis and diuretics, single doses of Zestril resulted in decreases in pulmonary capillary wedge pressure, systemic vascular resistance and blood pressure accompanied by an increase in cardiac output and no change in heart rate.

14.3 Acute Myocardial Infarction

The Gruppo Italiano per lo Studio della Sopravvienza nell'Infarto Miocardico (GISSI-3) study was a multicenter, controlled, randomized, unblinded clinical trial conducted in 19,394 patients with acute myocardial infarction (MI) admitted to a coronary care unit. It was designed to examine the effects of short-term (6 week) treatment with lisinopril, nitrates, their combination, or no therapy on short-term (6 week) mortality and on long-term death and markedly impaired cardiac function. Hemodynamically- stable patients presenting within 24 hours of the onset of symptoms were randomized, in a 2 x 2 factorial design, to six weeks of either 1) Zestril alone (n=4841), 2) nitrates alone (n=4869), 3) Zestril plus nitrates (n=4841), or 4) open control (n=4843). All patients received routine therapies, including thrombolytics (72%), aspirin (84%), and a beta blocker (31%), as appropriate, normally utilized in acute myocardial infarction (MI) patients.

The protocol excluded patients with hypotension (systolic blood pressure \leq 100 mmHg), severe heart failure, cardiogenic shock, and renal dysfunction (serum creatinine > 2 mg per dL and/or proteinuria > 500 mg per 24 h). Patients randomized to Zestril received 5 mg within 24 hours of the onset of symptoms, 5 mg after 24 hours, and then 10 mg daily thereafter. Patients with systolic blood pressure less than 120 mmHg at baseline received 2.5 mg of Zestril. If hypotension occurred, the Zestril dose was reduced or if severe hypotension occurred Zestril was stopped [see Dosage and Administration (2.3)].

The primary outcomes of the trial were the overall mortality at 6 weeks and a combined end point at 6 months after the myocardial infarction, consisting of the number of patients who died, had late (day 4) clinical congestive heart failure, or had extensive left ventricular damage defined as ejection fraction $\leq 35\%$ or an akinetic-dyskinetic [A-D] score $\geq 45\%$. Patients receiving Zestril (n=9646), alone or with nitrates, had an 11% lower risk of death (p = 0.04) compared to patients who did not receive Zestril (n=9672) (6.4% vs. 7.2%, respectively) at six weeks. Although patients randomized to receive Zestril for up to six weeks also fared numerically better on the combined end point at 6 months, the open nature of the assessment of heart failure, substantial loss to follow-up echocardiography, and substantial excess use of Zestril between 6 weeks and 6 months in the group randomized to 6 weeks of lisinopril, preclude any conclusion about this end point.

Patients with acute myocardial infarction, treated with Zestril, had a higher (9.0% versus 3.7%) incidence of persistent hypotension (systolic blood pressure < 90 mmHg for more than 1 hour) and renal dysfunction (2.4% versus 1.1%) in-hospital and at six weeks (increasing creatinine concentration to over 3 mg per dL or a doubling or more of the baseline serum creatinine concentration) [see Adverse Reactions (6.1)].

16 HOW SUPPLIED/STORAGE AND HANDLING

Zestril is available as uncoated biconvex tablets in bottles of 90.

Strength	Color	Shape	Scored	Side 1/Side 2	Bottle Count	NDC 24979-
2.5 mg	White	Round	No	ZESTRIL 2½/135	90 Tablets	238-07
5 mg	Pink	Capsule-	Yes	ZESTRIL/130	90 Tablets	239-07

		Shaped				
10 mg	Pink	Round	No	ZESTRIL 10/131	90 Tablets	240-07
20 mg	Pale Brownish Red	Round	No	ZESTRIL 20/132	90 Tablets	241-07
30 mg	Pale Brownish Red	Round	No	ZESTRIL 30/133	90 Tablets	242-07
40 mg	Yellow	Round	No	ZESTRIL 40/134	90 Tablets	243-07

Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.

17 PATIENT COUNSELING INFORMATION

NOTE: This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Pregnancy: Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider with a known or suspected pregnancy [see Warnings and *Precautions (5.1)* and *Use in Specific Populations (8.1)*].

Angioedema: Angioedema, including laryngeal edema may occur at any time during treatment with angiotensin converting enzyme inhibitors, including Zestril. Tell patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

Lactation: Advise women not to breastfeed during treatment with Zestril [see Use in Specific Populations (8.2)]

Symptomatic Hypotension: Tell patients to report light-headedness especially during the first few days of therapy. If actual syncope occurs, tell the patient to discontinue the drug until they have consulted with the prescribing physician.

Tell patients that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; advise patients accordingly.

Hyperkalemia: Tell patients not to use salt substitutes containing potassium without consulting their physician.

Hypoglycemia: Tell diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor to monitor for hypoglycaemia closely, especially during the first month of combined use [see *Drug Interactions (7.2)*].

Leukopenia/Neutropenia: Tell patients to report promptly any indication of infection (e.g., sore throat, fever), which may be a sign of leukopenia/neutropenia.

Zestril is a registered trademark of TWi Pharmaceuticals, Inc.

Distributed by: TWi Pharmaceuticals USA, Inc. Paramus, NJ 07652

PKG03122

Rev. 11/2023

NDC 24979-238-07

Rx only

ONCE-DAILY ZESTRIL[®] (LISINOPRIL)

2.5 mg tablets

90 tablets



NDC 24979-239-07

Rx only

ONCE-DAILY ZESTRIL®

(LISINOPRIL)

5 mg tablets

90 tablets



NDC 24979-240-07

Rx only

ONCE-DAILY ZESTRIL[®] (LISINOPRIL)

(LISINOPRIL)

10 mg tablets

90 tablets



NDC 24979-241-07

Rx only

ONCE-DAILY ZESTRIL[®] (LISINOPRIL)

20 mg tablets

90 tablets



NDC 24979-242-07

Rx only

ONCE-DAILY ZESTRIL®

(LISINOPRIL)

30 mg tablets

90 tablets



NDC 24979-243-07

Rx only

ONCE-DAILY ZESTRIL[®] (LISINOPRIL)

40 mg tablets

90 tablets

	NDC 24979-243-07	Rx only	USUAL DOSAGE: See accompanying Prescribing Information.	
TWI Pha	ONCE-DAILY ®		WARNING: As with all medications, keep out of the reach of children.	
is a trademark of rmaceuticals, Inc.	(LISINOPRIL)		Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture, freezing and excessive heat.	0 h T E (
2430	40 mg tablets		Dispense in a tight container.	теоэха
78	90 tablets		Distributed by: TWi Pharmaceuticals USA, Inc. Paramus, NJ 07652	
	TW		Rev. 01/2024	

ZESTRIL

lisinopril tablet

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24979-238
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)	LISINOPRIL	2.5 mg

Inactive Ingredients

Strength

Product Characteristics

Color	WHITE	Score	no score
Shape	ROUND (biconvex)	Size	7mm
Flavor		Imprint Code	ZESTRIL;2;1;2;135
Contains			

F	Packaging			
#	tem Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24979-238- 07	90 in 1 BOTTLE; Type 0: Not a Combination Product	04/25/2024	

Flavor Contains Packaging Item Code NDC:24979-239- 07 Marketing Category	90 in 1 BOTTL Product	Ckage Description E; Type 0: Not a Combin ion tion Number or Mon Citation		Da 04/25/2024 Marke	ng Start ite ting Start Date	Marke	ting End ate eting End Date
Contains Packaging # Item Code 1 NDC:24979-239- 07	90 in 1 BOTTL Product	E; Type 0: Not a Combin	ation	Da	-		_
Contains Packaging # Item Code 1 NDC:24979-239-	90 in 1 BOTTL		ation	Da	-		_
Contains Packaging # Item Code 1 NDC:24979-239-	90 in 1 BOTTL		ation	Da	-		_
Contains Packaging	Pac	ckage Description			-		_
Contains							
Flavor							
			Impri	nt Code		ZESTRIL;13)
Shape	CAPSULE (bi	convex)	Size			8mm	
Color	PINK		Score			2 pieces	
Product Chara	cteristics						
STARCH, CORN (UI		J)					
FERRIC OXIDE REE MANNITOL (UNII: 30		(כ/סב)					
MAGNESIUM STEA							
		DIHYDRATE (UNII: 07TS)	Z97GEP)				
		Ingredient Nam	е			S	trength
Inactive Ingre	dients						
LISINOPRIL (UNII: E	-	ISINOPRIL ANHYDROUS -	UNII:7Q3	P4BS2FD)	LISINOPRIL	Strength	5 mg
istine ingreat		edient Name			Basis of	Strength	Strengt
Active Ingredi	ent/Active	Moietv					
Route of Admini	stration	ORAL					
Product Type		HUMAN PRESCRIPTION	DRUG	Item Cod	e (Source) NDC:2	24979-239
Product Infor	mation						
isinopril tablet							
ZESTRIL							
	NDA019777	Citation		04/25/202		-	
NDA	Арриса	tion Number or Mon Citation	ograph		ting Start Date		eting End Date
Marketing Category NDA			0 0 r 0 0 0	Marka	ting Start	I I I I I KE	

ZESTRIL lisinopril tablet							
Product Infor	mation						
Product Type		HUMAN PRESCRIPT	ION DRUG	ltem Cod	e (Source)	NDC:2	24979-240
Route of Admin	istration	ORAL					
Active Ingred	ient/Active	Moiety					
	Ingr	edient Name			Basis of S	trength	Strength
LISINOPRIL (UNII: I	E7199S1YWR) (L	ISINOPRIL ANHYDRO	US - UNII:7Q3P	4BS2FD)	LISINOPRIL		10 mg
Inactive Ingre	dients						
		Ingredient N	lame			S	trength
DIBASIC CALCIUM	I PHOSPHATE	DIHYDRATE (UNII: C	07TSZ97GEP)				
MAGNESIUM STEA	ARATE (UNII: 70	097M6I30)					
	D (UNII: 1K09F3	G675)					
FERRIC OXIDE RE MANNITOL (UNII: 3	OWL53L36A)						
FERRIC OXIDE RE MANNITOL (UNII: 3	OWL53L36A)						
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U	OWL53L36A) NII: 08232NY3S						
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara	OWL53L36A) NII: 08232NY3S		Score		no sco	ore	
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color	OWL53L36A) NII: 08232NY35 acteristics	J)	Score Size		no sco 8mm	ore	
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape	OWL53L36A) NII: O8232NY3S Acteristics PINK	J)		ode	8mm	ore RIL10;131	
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor	OWL53L36A) NII: O8232NY3S Acteristics PINK	J)	Size	ode	8mm		
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor Contains	OWL53L36A) NII: O8232NY3S Acteristics PINK	J)	Size	ode	8mm		
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor Contains Packaging # Item Code	OWL53L36A) NII: O8232NY3S Acteristics PINK ROUND (bicc	J) onvex) ckage Descripti	Size Imprint Co		8mm ZESTF	RIL10;131 Market	ting End ate
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor Contains Packaging # Item Code	OWL53L36A) NII: O8232NY3S Acteristics PINK ROUND (bicc	J) onvex)	Size Imprint Co	Marketi	8mm ZESTF	RIL10;131 Market	<u> </u>
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor Contains Packaging # Item Code 1 NDC:24979-240- 07	OWL53L36A) NII: O8232NY3S ACTERISTICS PINK ROUND (bico ROUND (bico 90 in 1 BOTTL Product	J) onvex) ckage Descripti .E; Type 0: Not a Cor	Size Imprint Co	Marketi Da	8mm ZESTF	RIL10;131 Market	<u> </u>
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor Contains Packaging # Item Code 1 NDC:24979-240- 07	OWL53L36A) NII: O8232NY3S ACTERISTICS PINK ROUND (bico ROUND (bico 90 in 1 BOTTL Product	J) onvex) ckage Descripti .E; Type 0: Not a Cor	Size Imprint Co	Marketi Da	8mm ZESTF	RIL10;131 Market	-
FERRIC OXIDE RE MANNITOL (UNII: 3 STARCH, CORN (U Product Chara Color Shape Flavor Contains Packaging # Item Code 1 NDC:24979-240-	OWL53L36A) NII: O8232NY35 ACTERISTICS PINK ROUND (bicd PO in 1 BOTTL Product	J) onvex) ckage Descripti .E; Type 0: Not a Cor	Size Imprint Co on mbination	Marketin Da 04/25/2024 Marke	8mm ZESTF	Market Market D	<u> </u>

ZESTRIL

lisinopril tablet

Product Type							
		HUMAN PRESCRIPTION D	RUG	ltem Cod	e (Source)	NDC:2	4979-241
Route of Adm	inistration	ORAL					
Activo Inar	edient/Active	Mojety					
Active mgre		•			Decis of Ctu		Ctranst
LISINOPRIL (UN	•	edient Name LISINOPRIL ANHYDROUS - U	JNII:703P4	IBS2ED)	Basis of Str	ength	20 mg
(011			, , , , , , , , , , , , , , , , , , ,				20 mg
Inactive Ing	redients						
		Ingredient Name				S	trength
		DIHYDRATE (UNII: 07TSZ	.97GEP)				
	TEARATE (UNII: 70	· ·					
	RED (UNII: 1K09F3	60/5)					
MANNITOL (UNI	I: 30WL53L36A) (UNII: 08232NY35	<u>`</u> 1\					
		-					
Product Cha	aracteristics						
Color	RED	Sc	ore		no score	9	
Shape	ROUND (bice	onvex) Si	ze		8mm		
Flavor							
		Im	nprint Co	ae	ZESTRIL	.20;132	
Contains		Im	nprint Co	ae	ZESTRIL	.20;132	
Contains		Im	nprint Co	ae	ZESTRIL	.20;132	
Contains Packaging		Im	nprint Co	de	ZESTRIL	.20;132	
Packaging	e Pa	Im ckage Description	nprint Co	ode Marketii Da	ng Start	Market	ing End
Packaging # Item Cod			tion	Marketii	ng Start	Market	
Packaging # Item Cod	41- 90 in 1 BOTTI	ckage Description	tion	Marketii Da	ng Start	Market	
Packaging # Item Cod 1 NDC:24979-24 07	41- 90 in 1 BOTTI	ckage Description _E; Type 0: Not a Combina	tion	Marketii Da	ng Start	Market	
Packaging # Item Cod 1 NDC:24979-24 07	41- 90 in 1 BOTTI Product g Informat g Applica	ckage Description _E; Type 0: Not a Combina	ition 0	Marketin Da 4/25/2024 Marke	ng Start	Market Da Marke	ate
Packaging # Item Cod 1 NDC:24979-24 07 Marketing Marketing	41- 90 in 1 BOTTI Product g Informat g Applica	ckage Description LE; Type 0: Not a Combina :ion tion Number or Mono Citation	ition 0	Marketin Da 4/25/2024 Marke	ng Start te ting Start Date	Market Da Marke	ate ting End
Packaging # Item Cod 1 NDC:24979-24 07 Marketing Category	41- 90 in 1 BOTTI Product g Informat Applica	ckage Description LE; Type 0: Not a Combina :ion tion Number or Mono Citation	ition 0	Marketii Da 4/25/2024 Marke	ng Start te ting Start Date	Market Da Marke	ate ting End
Packaging # Item Cod 1 NDC:24979-24 07 Marketing Category	41- 90 in 1 BOTTI Product g Informat Applica	ckage Description LE; Type 0: Not a Combina :ion tion Number or Mono Citation	ition 0	Marketii Da 4/25/2024 Marke	ng Start te ting Start Date	Market Da Marke	ate ting End

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24979-242
Route of Administration	ORAL		

Active Ingredi	ent/Active	Moiety						
	Ingr	edient Name			Basis of S	trength	Strength	
LISINOPRIL (UNII: E	7199S1YWR)(L	ISINOPRIL ANHYDROUS	5 - UNII:7Q3	P4BS2FD)	LISINOPRIL		30 mg	
Inactive Ingre	dients							
		Ingredient Na	me			S	trength	
		DIHYDRATE (UNII: 07	TSZ97GEP)					
MAGNESIUM STEA								
FERRIC OXIDE RED		G675)						
MANNITOL (UNII: 30								
STARCH, CORN (UN	NII: 08232NY3S	J)						
Product Chara	cteristics							
Color	RED		Score		no sco	ore		
Shape	ROUND (bico	nvex)	Size		9mm			
Flavor			Imprint C	Code	ZESTR	RIL30;133		
Contains								
Packaging								
# Item Code	Pac	kage Description	n	Marketing Start N Date			Marketing End Date	
1 NDC:24979-242- 07	90 in 1 BOTTL Product	E; Type 0: Not a Comb	pination	04/25/2024		_		
07	rioduct							
Marketing I	Informat	ion						
Marketing Category	Applicat	tion Number or Monograph Citation		Marketing Start Date		Marketing End Date		
NDA	NDA019777	Citation		04/25/202			Jale	
	NDA019777			04/23/202				
ZESTRIL								
isinopril tablet								
Product Infor	mation							
Product Type		HUMAN PRESCRIPTIO	N DRUG	ltem Cod	le (Source)	NDC:2	4979-243	
Route of Admini	stration	ORAL						
Active Ingredi	ent/Active	Moiety						
i cure nigreak		edient Name			Basis of S	trongth	Strongt	
		ISINOPRIL ANHYDROUS				uengui		
	7199311VK) (L		- UNII: /Q3	HDSZFU)	LISINOPKIL		40 mg	

		nts				
			ient Name			Strength
DIBASIC CAL	сіим рно	OSPHATE DIHYDRATE	(UNII: O7TSZ97GEP)			
MAGNESIUM	STEARAT	E (UNII: 70097M6I30)				
MANNITOL (U	NII: 30WL	53L36A)				
STARCH, COP	RN (UNII: C	08232NY3SJ)				
FERRIC OXID	E YELLOV	N (UNII: EX438O2MRT)				
Product C	haracte	eristics				
Color	Y	ELLOW	Score		no score	
Shape	R	OUND (biconvex)	Size		8mm	
Flavor			Imprint C	Code	ZESTRIL40;134	
Contains						
Packaging	J					
		Package Des	cription	Marketing Sta Date	art M	larketing End Date
# Item Co	de -243- 90	Package Des in 1 BOTTLE; Type 0: No educt	-		art M	
1 NDC:24979-	de -243- 90	in 1 BOTTLE; Type 0: No	-	Date	art M	
# Item Co 1 NDC:24979- 07	o de -243- 90 Pro	in 1 BOTTLE; Type 0: No	-	Date	art M	
# Item Co 1 NDC:24979- 07	o de -243- 90 Pro	in 1 BOTTLE; Type 0: No	-	Date	art M	
# Item Co 1 NDC:24979- 07	ode 243- 90 Pro ng Inf	in 1 BOTTLE; Type 0: No	er or Monograph	Date		

Labeler - TWi Pharmaceuticals, Inc. (658402052)

Registrant - TWi Pharmaceuticals, Inc. (658402052)

Revised: 1/2024

TWi Pharmaceuticals, Inc.